See more : Centuria Industrial REIT (CIP.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Corcept Therapeutics Incorporated (CORT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corcept Therapeutics Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tingyi (Cayman Islands) Holding Corp. (910322.TW) Income Statement Analysis – Financial Results
- Harmony Biosciences Holdings, Inc. (HRMY) Income Statement Analysis – Financial Results
- RepliCel Life Sciences Inc. (REPCF) Income Statement Analysis – Financial Results
- De La Rue plc (DELRF) Income Statement Analysis – Financial Results
- adidas AG (ADDDF) Income Statement Analysis – Financial Results
Corcept Therapeutics Incorporated (CORT)
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 482.38M | 401.86M | 365.98M | 353.87M | 306.49M | 251.25M | 159.20M | 81.32M | 50.29M | 26.55M | 10.36M | 3.31M | 0.00 | 0.00 | 29.00K | 209.00K | 482.00K | 294.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.48M | 5.39M | 5.28M | 5.58M | 5.50M | 5.22M | 3.55M | 2.06M | 1.36M | 882.00K | 143.00K | 91.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 475.89M | 396.47M | 360.70M | 348.29M | 300.98M | 246.03M | 155.65M | 79.26M | 48.93M | 25.67M | 10.21M | 3.22M | 0.00 | 0.00 | 29.00K | 209.00K | 482.00K | 294.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.66% | 98.66% | 98.56% | 98.42% | 98.20% | 97.92% | 97.77% | 97.47% | 97.29% | 96.68% | 98.62% | 97.25% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 184.35M | 130.99M | 113.86M | 114.76M | 89.02M | 75.25M | 40.38M | 23.84M | 15.42M | 18.37M | 20.47M | 14.07M | 21.00M | 18.95M | 14.40M | 14.15M | 7.86M | 20.83M | 17.07M | 11.55M | 8.11M | 13.26M | 5.39M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.33M | 8.49M | 5.88M | 5.75M | 4.87M | 5.04M | 4.08M | 4.49B | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.49B | 0.00 | 0.00 | 0.00 |
| SG&A | 184.26M | 152.85M | 122.36M | 105.33M | 100.36M | 81.29M | 62.42M | 45.24M | 36.95M | 34.92M | 31.24M | 25.41M | 11.33M | 8.49M | 5.88M | 5.75M | 4.87M | 5.04M | 4.08M | 4.49M | 1.89M | 5.53M | 2.62M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.44M | 6.59M | 4.33M | 4.39M | 4.02M | 4.03M | 3.29M | 3.02B | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 368.61M | 283.84M | 236.22M | 220.09M | 189.38M | 156.54M | 102.79M | 69.08M | 52.37M | 53.29M | 51.71M | 39.49M | 32.33M | 27.44M | 20.28M | 19.90M | 12.73M | 25.88M | 21.16M | 16.04M | 9.99M | 18.80M | 8.01M |
| Cost & Expenses | 375.09M | 289.22M | 241.50M | 225.67M | 194.88M | 161.75M | 106.35M | 71.14M | 53.73M | 54.17M | 51.85M | 39.58M | 32.33M | 27.44M | 20.28M | 19.90M | 12.73M | 25.88M | 21.16M | 16.04M | 9.99M | 18.80M | 8.01M |
| Interest Income | 17.28M | 3.56M | 529.00K | 3.40M | 5.07M | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.56M | 0.00 | 0.00 | 5.07M | 2.66M | 49.00K | 2.04M | 2.97M | 3.76M | 4.52M | 1.78M | 3.00K | 1.50M | 101.00K | 944.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.04M | 2.97M | 3.07M | 2.24M | 2.17M | 236.00K | 106.00K | 87.00K | 155.00K | 141.00K | 74.00K | 27.00K | 3.00K | 6.00K | 10.00K | 12.00K | 13.00K | 14.00K | 704.00K | 1.61M | 22.55K | 0.00 | 0.00 |
| EBITDA | 108.32M | 112.63M | 124.48M | 130.44M | 113.78M | 89.73M | 52.96M | 10.27M | -3.29M | -27.48M | -41.42M | -36.25M | -32.35M | -25.96M | -20.25M | -19.69M | -12.25M | -25.58M | -20.09M | -15.47M | -9.97M | -18.80M | -8.01M |
| EBITDA Ratio | 22.46% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.20% | 12.62% | -6.54% | -103.49% | -399.94% | -1,096.01% | 0.00% | 0.00% | -69,734.48% | -8,785.17% | -2,534.44% | -8,693.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 107.28M | 112.63M | 124.48M | 128.20M | 111.61M | 89.50M | 52.86M | 10.18M | -3.44M | -27.62M | -41.50M | -36.27M | -32.33M | -27.44M | -20.25M | -19.69M | -12.25M | -25.58M | -21.16M | -16.04M | -9.99M | -18.80M | -8.01M |
| Operating Income Ratio | 22.24% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.20% | 12.52% | -6.85% | -104.02% | -400.66% | -1,096.82% | 0.00% | 0.00% | -69,827.59% | -9,420.57% | -2,540.46% | -8,701.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.28M | 3.56M | 529.00K | 3.40M | 5.07M | 2.66M | -49.00K | -2.04M | -2.97M | -3.76M | -4.52M | -1.78M | -22.00K | 1.47M | 84.00K | -372.00K | 672.00K | 709.00K | 1.07M | 510.35K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 124.56M | 116.19M | 125.01M | 131.60M | 116.68M | 92.15M | 52.81M | 8.14M | -6.41M | -31.38M | -46.01M | -38.05M | -32.35M | -25.97M | -20.17M | -20.06M | -11.57M | -24.87M | -20.09M | -15.53B | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 25.82% | 28.91% | 34.16% | 37.19% | 38.07% | 36.68% | 33.17% | 10.01% | -12.74% | -118.20% | -444.25% | -1,150.53% | 0.00% | 0.00% | -69,537.93% | -9,598.56% | -2,401.04% | -8,460.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 18.42M | 14.77M | 12.49M | 25.59M | 22.50M | 16.74M | -76.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.00K | -1.47M | -84.00K | 372.00K | -672.00K | -709.00K | -1.07M | -510.35K | -182.23K | 18.50M | 7.45M |
| Net Income | 106.14M | 101.42M | 112.51M | 106.01M | 94.18M | 75.41M | 129.12M | 8.14M | -6.41M | -31.38M | -46.01M | -38.05M | -32.35M | -25.97M | -20.17M | -20.06M | -11.57M | -24.87M | -20.09M | -15.53M | -9.81M | -18.50M | -7.45M |
| Net Income Ratio | 22.00% | 25.24% | 30.74% | 29.96% | 30.73% | 30.01% | 81.11% | 10.01% | -12.74% | -118.20% | -444.25% | -1,150.53% | 0.00% | 0.00% | -69,537.93% | -9,598.56% | -2,401.04% | -8,460.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.02 | 0.95 | 0.97 | 0.92 | 0.82 | 0.60 | 1.14 | 0.07 | -0.06 | -0.31 | -0.46 | -0.41 | -0.39 | -0.38 | -0.38 | -0.43 | -0.34 | -1.09 | -0.89 | -0.84 | -1.13 | -2.75 | -1.39 |
| EPS Diluted | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 | 0.60 | 1.04 | 0.07 | -0.06 | -0.31 | -0.46 | -0.41 | -0.39 | -0.38 | -0.38 | -0.43 | -0.34 | -1.09 | -0.89 | -0.84 | -1.13 | -2.75 | -1.39 |
| Weighted Avg Shares Out | 103.56M | 106.79M | 115.65M | 115.41M | 114.35M | 125.68M | 113.53M | 110.57M | 106.80M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | 52.44M | 46.72M | 34.25M | 22.84M | 22.61M | 18.44M | 8.65M | 6.72M | 5.38M |
| Weighted Avg Shares Out (Dil) | 111.74M | 115.97M | 125.96M | 124.19M | 122.57M | 126.69M | 124.52M | 116.14M | 106.88M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | 52.44M | 46.72M | 34.25M | 22.84M | 22.61M | 18.44M | 8.65M | 6.72M | 5.38M |
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024.
Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Conference Call Participants David...
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.28 per share a year ago.
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results...
Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. JD, SKWD, CORT & PRA are well-poised to gain.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IDR, QFIN, SEZL, CORT, FINW.
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?
The mean of analysts' price targets for Corcept (CORT) points to a 43% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Corcept: Key Announcements Coming Soon
Corcept's upcoming Q4 announcements include pivotal trial results for Relacorilant in ovarian cancer, Dazucorilant in ALS, and an NDA filing for Relacorilant in Cushing's. Positive results from these trials could significantly boost CORT's revenue potential, especially in non-Cushing's applications like...
Source: https://incomestatements.info
Category: Stock Reports